查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1466819

角膜疤痕市场:初步研究 (KOL Insights) - 市场情报 - 流行病学和 2034 年市场预测

Corneal Scarring | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2034
出版日期: | 出版商: Mellalta Meets LLP | 英文 113 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

角膜疤痕市场主要由外用皮质类固醇和外用丝裂霉素C贡献。 到 2034 年，新兴治疗方法的采用将成为一个重大转折点，为角膜疤痕治疗市场带来巨大变化。 2020-2034年调查期间，被调查国家（美国、法国、德国、义大利、西班牙、英国、日本）用于角膜疤痕治疗的新兴疗法的销售额将以3.60%的复合年增长率增长，预计将增加57亿美元。

角膜疤痕，也称为角膜白斑或角膜混浊，是一个重要的问题，因为它会影响角膜清晰度和视觉功能。 角膜高度组织化的透明结构对于其将光线传输到视网膜的能力至关重要，当这种结构被破坏时，就会形成疤痕组织并可能损害视力。

角膜疤痕通常是纤维化细胞反应的结果，其目的是治癒组织，但无法恢復其透明度。 这是角膜疾病和损伤的一个主要问题，因为疤痕会导致永久性视力丧失。 与其他组织相比，疤痕组织形成对角膜的影响尤其显着，因为它直接影响视力。

本报告调查了七个主要国家的角膜疤痕市场，并提供了市场现状、疾病概述和治疗方法、患者趋势、区域趋势、未满足的需求和未来前景。

目录

第 1 章执行摘要

第2章角膜疤痕疾病的背景

  • 角膜疤痕简介
  • 角膜混浊分级
  • 角膜疤痕的征兆和症状
  • 角膜疤痕的原因与危险因子
  • 角膜疤痕的病因学

第3章角膜疤痕的诊断

  • 角膜疤痕的诊断

第 4 章流行病学与病患群体

  • 主要发现
  • 方法与资料来源
    • 各国角膜疤痕诊断实例
    • 各国角膜疤痕治疗实例
  • 角膜疤痕流行病学和模型参数的主要资讯来源
    • 美国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
    • 日本

第 5 章目前的治疗方法与医疗实务

  • 角膜疤痕的治疗与药物治疗
  • 当前角膜疤痕的临床药物治疗
  • 目前治疗角膜疤痕的手术方法
  • 常见的角膜移植类型

第 6 章角膜疤痕患者的趋势

  • 介绍路线
  • 诊断评估
  • 治疗评估
  • 治疗选择

第 7 章美国、四个欧盟国家、英国和日本未满足的需求

第8章新的治疗方法

  • 主要发现
  • 管道概览
  • 角膜疤痕领域的显着进展

第9章未来治疗典范

  • 角膜疤痕治疗的竞争格局和预期批准
  • 未来的治疗演算法与竞争定位
  • 新疗法关键数据摘要

第 10 章当前和新治疗方法的年度费用

第11章角膜疤痕后期治疗的策略考量

第12章市场展望

  • 主要发现
  • 摘要
  • 2034 年之前按国家划分的市场预测

第 13 章按国家划分的市场预测

  • 美国
  • 德国
  • 法国
  • 义大利
  • 西班牙
  • 英国
  • 日本

第14章市场促进因素与限制因素

第15章附录

简介目录

The Corneal Scarring market is hugely contributed using topical corticosteroids and local application of mitomycin C. By 2034, the uptake of novel emerging therapies will serve as a major breakpoint to get a drastic change in the Corneal Scarring therapeutics market. The sales of the emerging therapies for the treatment Corneal Scarring in the study countries (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) will experience high growth over the 2020-2034 study period, adding a value estimated at a total market of $5.7 Billion by 2034.

"Depending on the depth of the scar, different surgical procedures are recommended to remove the scar. In the outer layers of the cornea, the scar may be able to be peeled or scraped away. A scar in the middle layer may be able to be removed in a laser procedure known as PTK (Photo Therapeutic Keratectomy). Corneal transplants, either full or partial, can also be performed to remove the section of the cornea containing the scar."

Corneal Scarring, also known as corneal leukoma or corneal opacity, is a significant concern due to its impact on the transparency and visual function of the cornea. The cornea's highly organized and transparent structure is crucial for its function in transmitting light onto the retina, and any disruption to this architecture can lead to scar tissue formation, impairing vision.

Scarring in the cornea is often the result of fibrotic cellular responses, which, while aiming to heal the tissue, fail to restore its transparency. This is a major concern in corneal diseases and injuries, as scarring can lead to permanent vision loss. The impact of scar tissue formation in the cornea is particularly significant compared to other tissue types, as it directly affects vision.

Mellalta's Corneal Scarring Report- Market Summary

Market Size 2034: $5.7 billion

CAGR%: 3.60%

Key Market Players: Claris Biotherapeutics

Forecast Period: 2020-2034

Countries Covered: US, France, Germany, Italy, Spain, UK, China, and Japan.

Current SOC: Topical corticosteroids; Local application of mitomycin C;

Future SOC: Hepatocyte Growth Factor (HGF)

Key Unmet Need: Standardized Treatment Guidelines; Lack of Approved Pharmaceutical Interventions; Demand for Safer and More Efficacious Treatment Options

Key Insights: Given their affordability and accessibility, current SOC therapies remain viable options for a significant portion of patients.

Provider-Patient (PPP) Perspective: Cost-effectiveness of treatment; Better Diagnostic Identification; Access to appropriate treatments and improved options

Mellalta's Corneal Scarring Report - Epidemiology

The total prevalent cases of Corneal Scarring in the G7 countries are anticipated to increase by a significant number of cases by 2034 for the study period (2020-2034). This increase translates to a CAGR of approximately 0.6% over the 15-year forecast period, underscoring a steady escalation in the incidence of Corneal Scarring. As per estimates, the United States will present with the highest prevalence of Corneal Scarring cases in 2034. Among the EU5, Germany had the highest Corneal Scarring cases, followed by the UK, France, Italy, and Spain. Japan is reported to have the highest number of treated cases after the United States.

Mellalta's Corneal Scarring Report - Current Market Size & Forecast Trends

The Corneal Scarring therapeutics market is expected to experience high growth throughout our study period (i.e., 2020 to 2034) to USD 5.7 billion. The United States captured the highest market share as compared to the European 5 countries and Japan.

The current standard of care is limited to therapies such as prednisone acetate ophthalmic suspension, a topical corticosteroid, which is well-established for minimizing corneal scarring, leveraging its anti-inflammatory and antifibrotic properties. Corticosteroids have shown efficacy in reducing TGFb expression, which is considered a key mechanism for antifibrotic therapy in the cornea. MMC, on the other hand, is a potent mitotic inhibitor known for its chemotherapeutic applications. It works by covalently binding with DNA to inhibit synthesis processes, and as an eyedrop, it helps induce apoptosis in myofibroblasts and prevents keratocyte differentiation, playing a crucial role in the management of corneal scarring.

The complexity of treatment regimens, often involving polypharmacy with frequent dosing schedules, exacerbates compliance challenges, particularly among the working-age population where daily responsibilities may impede strict adherence. The introduction of multi agent medications could potentially streamline treatment processes, thereby improving compliance rates. Additionally, the scarcity of accessible written information on ocular chemical burns represents an informational gap that, if filled, could significantly aid in patient and caregiver understanding of the condition and its treatment. Leveraging educational resources and engaging patients' support networks are critical steps toward bolstering treatment adherence.

In the 2024-2034 forecast period, there will be tremendous growth and shift in therapeutic market with the launch of novel emerging therapies like CSB-001 (Claris Biotherapeutics) and others. The emerging therapies will likely replace existing treatments, reflecting a dynamic shift towards more advanced therapeutic options in the Corneal Scarring space and more.

Questions Answered

What is the size of clinically and commercially relevant drug-treatable Corneal Scarring populations, and how will drug-treatment rates change over time?

Potential challenges and opportunities in implementing approved therapy for Corneal Scarring.

What are the most promising agents in the pipeline, and how will they shape the future of this therapy market?

What key drivers and constraints will affect the Corneal Scarring therapy market over the forecast period?

Report Highlights

Corneal Scarring - Current Market Trends

Corneal Scarring - Current & Forecasted Cases across the G7 Countries

Corneal Scarring - Market Opportunities and Sales Potential for Agents

Corneal Scarring - Patient-based Market Forecast to 2034

Corneal Scarring - Untapped Business Opportunities

Corneal Scarring - Product Positioning Vis-a-vis Competitors' Products

Corneal Scarring - KOLs Insight

Table of Content

1.Executive Summary

  • 1.1.Key Findings
  • 1.2.Key Market Challenges and Opportunities
  • 1.3.What Do the Experts Say?

2.Corneal Scarring Disease Background

  • 2.1.Corneal Scarring Introduction
  • 2.2.Grading of Corneal Opacities
  • 2.3.Sign and Symptoms of Corneal Scarring
  • 2.4.Causes and Risk factors of Corneal Scarring
  • 2.5.Pathogenesis of Corneal Scarring

3.Corneal Scarring Diagnosis

  • 3.1.Diagnosis of Corneal Scarring

4.Epidemiology and Patient Populations

  • 4.1.Key Findings
  • 4.2.Methods and data Sources
    • 4.2.1.Country Specific Diagnosed Prevalent cases of Corneal Scarring
    • 4.2.2.Country Specific Treated cases of Corneal Scarring
  • 4.3.Key Sources for Corneal Scarring Epidemiology and Model Parameters
    • 4.3.1.United States
      • 4.3.1.1.United States Diagnosed Prevalent cases of Corneal Scarring
      • 4.3.1.2.United States Treated cases of Corneal Scarring
    • 4.3.2.Germany
      • 4.3.2.1.Germany Diagnosed Prevalent cases of Corneal Scarring
      • 4.3.2.2.Germany Treated cases of Corneal Scarring
    • 4.3.3.France
      • 4.3.3.1.France Diagnosed Prevalent cases of Corneal Scarring
      • 4.3.3.2.France Treated cases of Corneal Scarring
    • 4.3.4.Italy
      • 4.3.4.1.Italy Diagnosed Prevalent cases of Corneal Scarring
      • 4.3.4.2.Italy Treated cases of Corneal Scarring
    • 4.3.5.Spain
      • 4.3.5.1.Spain Diagnosed Prevalent cases of Corneal Scarring
      • 4.3.5.2.Spain Treated cases of Corneal Scarring
    • 4.3.6.United Kingdom
      • 4.3.6.1.United Kingdom Diagnosed Prevalent cases of Corneal Scarring
      • 4.3.6.2.United Kingdom Treated cases of Corneal Scarring
    • 4.3.7.Japan
      • 4.3.7.1.Japan Diagnosed Prevalent cases of Corneal Scarring
      • 4.3.7.2.Japan Treated cases of Corneal Scarring

5.Current Therapies and Medical Practice

  • 5.1.Treatment and Medical Practices of Corneal Scarring
  • 5.2.Current clinical drug approaches to Corneal Scarring
  • 5.3.Current surgical approaches to Corneal Scarring
  • 5.4.Common types of corneal transplantations

6.Patient Journey in Corneal Scarring

  • 6.1.Referral Routes
  • 6.2.Diagnosis Evaluation
  • 6.3.Treatment Evaluation
  • 6.4.Treatment Choice

7.Unmet Needs in US, EU4, UK, and JP

8.Emerging Therapies

  • 8.1.Key Findings
  • 8.2.Pipeline Overview
  • 8.3.Notable Developments in the Corneal Scarring space
    • 8.3.1.Product Analysis
      • 8.3.1.1.CSB-001 (Claris Biotherapeutics)
        • 8.3.1.1.1.Product Profile
        • 8.3.1.1.2.Clinical Development
        • 8.3.1.1.3.Market & Sales Opportunity Forecasted to 2034
      • 8.3.1.2.Not Exhaustive list (more drugs are covered..)

9.Future Treatment Paradigm

  • 9.1.Corneal Scarring Competitor Landscape and Approvals Anticipated
  • 9.2.Future Treatment Algorithms and Competitor Positioning
  • 9.3.Key Data Summary for Emerging Treatment

10.Annual Cost of Current & Emerging Treatment

11.Late Phase Therapies Strategic Considerations in Corneal Scarring

12.Market Outlook

  • 12.1.Key Findings
  • 12.2.Overview
  • 12.3.Country Specific Market Forecast to 2034
    • 12.3.1.Country Specific Market for Corneal Scarring 2019-2034 (USD Million)
    • 12.3.2.Country Specific Market for Corneal Scarring by Therapies 2019-2034 (USD Million)

13.Market Forecast by Country

  • 13.1.United States
    • 13.1.1.United States Market for Corneal Scarring 2019-2034 (USD Million)
    • 13.1.2.United States Market for Corneal Scarring by Therapies 2019-2034 (USD Million)
  • 13.2.Germany
    • 13.2.1.Germany Market for Corneal Scarring 2019-2034 (USD Million)
    • 13.2.2.Germany Market for Corneal Scarring by Therapies 2019-2034 (USD Million)
  • 13.3.France
    • 13.3.1.France Market for Corneal Scarring 2019-2034 (USD Million)
    • 13.3.2.France Market for Corneal Scarring by Therapies 2019-2034 (USD Million)
  • 13.4.Italy
    • 13.4.1.Italy Market for Corneal Scarring 2019-2034 (USD Million)
    • 13.4.2.Italy Market for Corneal Scarring by Therapies 2019-2034 (USD Million)
  • 13.5.Spain
    • 13.5.1.Spain Market for Corneal Scarring 2019-2034 (USD Million)
    • 13.5.2.Spain Market for Corneal Scarring by Therapies 2019-2034 (USD Million)
  • 13.6.United Kingdom
    • 13.6.1.United Kingdom Market for Corneal Scarring 2019-2034 (USD Million)
    • 13.6.2.United Kingdom Market for Corneal Scarring by Therapies 2019-2034 (USD Million)
  • 13.7.Japan
    • 13.7.1.Japan Market for Corneal Scarring 2019-2034 (USD Million)
    • 13.7.2.Japan Market for Corneal Scarring by Therapies 2019-2034 (USD Million)

14.Market Drivers and Constraints

    • 14.1.1.What Factors Are Driving the Market for Corneal Scarring?
    • 14.1.2.What Factors Are Constraining the Market for Corneal Scarring?

15.Appendix

  • 15.1.Methodology